Publication: Kronik bel ağrısında flurbiprofenin etkinliği: Plasebo kontrollü çift kör çalışma
Abstract
Dünyada kronik bel ağrısı artan insidansı, sosyal ve medikal etkileri nedeniyle majör bir problemdir. Daha çok çalışan gençleri ve orta yaş grubundan insanları etkiler. Bu çalışmada steroid olmayan bir antienflamatuar ilaç olan flurbiprofenin kronik bel ağrısı üzerine etkinliğini araştırmayı amaçladık. Hastalar 20'şer kişilik iki gruba ayrıldı. Birinci gruba 100 mg'lık flurbiprofen tabletlerinden günde iki kez olmak üzere toplam 200 mg., ikinci gruba ise plasebo verildi. Hastalar çalışmanın başlangıcında, birinci ve dördüncü haftalarda Artrit Etki Ölçeği (AEÖ), Beck Depresyon Ölçeği (BDÖ), Görsel Analog Skalası (GAS) ile değerlendirildi. Ayrıca ilacın etkinliği 4 dereceli bir skala ile sorgulandı. Yan etkiler ve laboratuvar değerleri dokümente edildi. Tedavi grubunda AEÖ ile ölçülen duygu durumu ile hekim ve hastanın değerlendirdiği 4 dereceli ilaç etkinliği skalası skorlarında 4. haftada istatistiksel olarak anlamlı düzelme görülürken, 1. hafta skorlarında bir değişme görülmedi. Çalışmamızda flurbiprofen kullanımının kronik bel ağrısında depresyon skorlarını etkilemediği ancak analjezik yönden semptomatik etkinliği sebebi ile fonksiyonel durumda iyileşmeye yol açtığı sonucuna varıldı.
Chronic low back pain is major challenge for all societies because of its increasing incidence, social and medical implications. This condition continues to affect a significant proportion of working population among the young and middle-age adults. Forty patients diagnosed as chronic low-back pain were enrolled in a double blind, randomized trial designed to investigate the clinical efficacy of flurbiprofen. Each group consisted of 20 patients receiving either 100 mg flurbiprofen tablets twice daily (BID) or placebo respectively. Clinical evaluation was' realized by the patient on a pain visual analogue scale (VAS), four point verbal rating scale for general (both for patient and physician) well-being, Arthritis Impact Measurement Scale (AIMS) and Beck Depression Scale (BDS) at baseline and on weeks 1 and 4. Adverse events and laboratory assessments were documented. The affect subgroup of AIMS questionnaire and both patient's and physician's verbal rating scale scores showed statistically significant differences in favor of flurbiprofen group on week 4 but no difference on week 1. This study shows that the use of flurbiprofen in chronic low back pain has no effect on depression scores. But due to its analgesic and symptomatic effect, it may help to restore the functional status of the chronic low back pain patients.
Chronic low back pain is major challenge for all societies because of its increasing incidence, social and medical implications. This condition continues to affect a significant proportion of working population among the young and middle-age adults. Forty patients diagnosed as chronic low-back pain were enrolled in a double blind, randomized trial designed to investigate the clinical efficacy of flurbiprofen. Each group consisted of 20 patients receiving either 100 mg flurbiprofen tablets twice daily (BID) or placebo respectively. Clinical evaluation was' realized by the patient on a pain visual analogue scale (VAS), four point verbal rating scale for general (both for patient and physician) well-being, Arthritis Impact Measurement Scale (AIMS) and Beck Depression Scale (BDS) at baseline and on weeks 1 and 4. Adverse events and laboratory assessments were documented. The affect subgroup of AIMS questionnaire and both patient's and physician's verbal rating scale scores showed statistically significant differences in favor of flurbiprofen group on week 4 but no difference on week 1. This study shows that the use of flurbiprofen in chronic low back pain has no effect on depression scores. But due to its analgesic and symptomatic effect, it may help to restore the functional status of the chronic low back pain patients.